Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 9 Next >
PCB litigation: Washington Supreme Court ruling in Erickson
From Bayer
Via Business Wire
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
From Bayer
Via Business Wire
Tickers BAYRY BAYZF
Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology
From Bayer
Via Business Wire
Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
One A Day® Launches First of its Kind Multivitamin Gummy with Iron to Help Fill Nutrient Gaps in Kids
From Bayer
Via Business Wire
U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review
From Bayer
Via Business Wire
BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases
From Bayer
Via Business Wire
Bayer Appoints Priyal Patel as Chief Financial Officer for North America
From Bayer
Via Business Wire
U.S. Supreme Court Asks for Views of Solicitor General in Durnell Case
From Bayer
Via Business Wire
Bayer Files for Approval of gadoquatrane in the U.S.
From Bayer
Via Business Wire
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
From Bayer
Via Business Wire
U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer
From Bayer
Via Business Wire
Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress
From Bayer
Via Business Wire
Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated With Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study
From Bayer
Via Business Wire
CORRECTING and REPLACING New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology
From Bayer
Via Business Wire
U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
ASCO 2025: XOFIGO® (radium-223 dichloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
From Bayer
Via Business Wire
ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT
From Bayer
Via Business Wire
Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.